Journal Mobile Options
Table of Contents
Vol. 11, No. 2, 2013
Issue release date: November 2012
Neurodegenerative Dis 2013;11:72–78

Delay Discounting of Reward and Caudate Nucleus Volume in Individuals with α-Synuclein Gene Duplication before and after the Development of Parkinson’s Disease

Szamosi A. · Nagy H. · Kéri S.
aNational Psychiatry Center, bNational Institute for Medical Rehabilitation, and cDepartment of Neurology, Semmelweis University, Budapest, and dDepartment of Physiology, Faculty of Medicine, University of Szeged, Szeged, Hungary

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: α-Synuclein (SNCA) may be a key factor in dopaminergic neurotransmission, reward processing, and neurodegeneration in Parkinson’s disease (PD). We investigated delay discounting of reward and caudate volume in SNCA gene duplication carriers before and after the development of PD. Methods: Participants were 7 presymptomatic SNCA duplication carriers who later developed PD (follow-up period: 5.4 years) and 10 matched non-carrier controls. At the follow-up assessment, patients received levodopa (l-DOPA) therapy. Delay discounting of reward was assessed with the Kirby discounting questionnaire. We measured the volume of the caudate nucleus and cerebral cortex using structural MRI and FreeSurfer software. Results: In the presymptomatic stage, carriers showed similar delay discounting and caudate volume to that of non-carrier controls. However, after the development of PD, we observed a significant elevation in delay discounting (impulsive decisions) and reduced caudate volume. There was no cortical atrophy. Conclusion: Impaired reward-related decision making and caudate volume loss are not detectable in the presymptomatic stage in SNCA duplication carriers. These behavioral and neuroanatomical alterations are observed after the development of clinical symptoms when there is extensive neurodegeneration. Study limitations include a small sample size as well as the potential confounding effect of general cognitive decline.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al: Alpha-synuclein locus triplication causes Parkinson’s disease. Science 2003;302:841.
  2. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al: Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 2004;364:1167–1169.
  3. Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, et al: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008;70:43–49.
  4. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, et al: Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008;63:743–750.
  5. Onoda K, Okamoto Y, Kunisato Y, Aoyama S, Shishida K, Okada G, et al: Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 2009;24:1811–1819.

    External Resources

  6. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al: Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010;65:66–79.
  7. Lundblad M, Decressac M, Mattsson B, Björklund A: Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 2012;109:3213–3219.
  8. Yavich L, Oksman M, Tanila H, Kerokoski P, Hiltunen M, van Groen T, et al: Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis 2005;20:303–313.
  9. Oksman M, Tanila H, Yavich L: Brain reward in the absence of alpha-synuclein. Neuroreport 2006;17:1191–1194.
  10. Kéri S, Moustafa AA, Myers CE, Benedek G, Gluck MA: α-Synuclein gene duplication impairs reward learning. Proc Natl Acad Sci USA 2010;107:15992–15994.
  11. Kirby KN, Petry NM, Bickel WK: Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 1999;128:78–87.
  12. Ainslie G: Specious reward: a behavioral theory of impulsiveness and impulse control. Psychol Bull 1975;82:463–496.
  13. Hoffman WF, Schwartz DL, Huckans MS, McFarland BH, Meiri G, Stevens AA, Mitchell SH: Cortical activation during delay discounting in abstinent methamphetamine dependent individuals. Psychopharmacology (Berl) 2008;201:183–193.
  14. Marco-Pallarés J, Mohammadi B, Samii A, Münte TF: Brain activations reflect individual discount rates in intertemporal choice. Brain Res 2010;1320:123–129.
  15. Paloyelis Y, Asherson P, Mehta MA, Faraone SV, Kuntsi J: DAT1 and COMT effects on delay discounting and trait impulsivity in male adolescents with attention deficit/hyperactivity disorder and healthy controls. Neuropsychopharmacology 2010;35:2414–2426.

    External Resources

  16. Schweighofer N, Yamaguchi S, Doya K, Yamawaki S: Inter-individual discount factor differences in reward prediction are topographically associated with caudate activation. Exp Brain Res 2011;212:593–601.

    External Resources

  17. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
  18. Lang AE, Fahn S: Assessment of Parkinson’s disease; in Munsat TL (ed): Quantification of Neurologic Deficit. Boston, Butterworth-Heinemann. 1989, pp 285–309.
  19. Hoehn M, Yahr M: Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
  20. Voon V, Fox SH: Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64:1089–1096.
  21. Weintraub D, Nirenberg M: Impulse control and related disorders in Parkinson’s disease. Neurodegener Dis DOI: 10.1159/000341996.

    External Resources

  22. Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  23. Green L, Myerson J: A discounting framework for choice with delayed and probabilistic rewards. Psychol Bull 2004;130:769–792.
  24. Fischl B, Salat DH, van der Kouwe AJ, Makris N, Ségonne F, Quinn BT, Dale AM: Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004;23(suppl 1):S69–S84.
  25. Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, Fischl B: A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004;22:1060–1075.
  26. Housden CR, O’Sullivan SS, Joyce EM, Lees AJ, Roiser JP: Intact reward learning but elevated delay discounting in Parkinson’s disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 2010;35:2155–2164.
  27. Messina D, Cerasa A, Condino F, Arabia G, Novellino F, Nicoletti G, et al: Patterns of brain atrophy in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord 2011;17:172–176.

    External Resources

  28. Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, Quinn NP: Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697–702.
  29. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC: Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord 2006;21:989–996.
  30. Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, et al: MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246:214–221.
  31. Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, Kwon DY: Regional volume analysis of the Parkinson disease brain in early disease stage: gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol 2011;32:682–687.
  32. Ibarretxe-Bilbao N, Tolosa E, Junque C, Marti MJ: MRI and cognitive impairment in Parkinson’s disease. Mov Disord 2009;24 (suppl 2):S748–S753.

    External Resources

  33. Glenn AL, Raine A, Yaralian PS, Yang Y: Increased volume of the striatum in psychopathic individuals. Biol Psychiatry 2010;67:52–58.

    External Resources

  34. Voelbel GT, Bates ME, Buckman JF, Pandina G, Hendren RL: Caudate nucleus volume and cognitive performance: are they related in childhood psychopathology? Biol Psychiatry 2006;60:942–950.

    External Resources

  35. Ersche KD, Barnes A, Jones PS, Morein-Zamir S, Robbins TW, Bullmore ET: Abnormal structure of frontostriatal brain systems is associated with aspects of impulsivity and compulsivity in cocaine dependence. Brain 2011;134:2013–2024.

    External Resources

  36. Schultz W: Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 2006;57:87–115.
  37. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L: Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 2011;10:1015–1025.
  38. Hinault MP, Farina-Henriquez-Cuendet A, Goloubinoff P: Molecular chaperone and associated cellular clearance mechanisms against toxic protein conformers in Parkinson’s disease. Neurodegener Dis 2011;8:397–412.
  39. Kéri S, Nagy H, Myers CE, Benedek G, Shohamy D, Gluck MA: Risk and protective haplotypes of the alpha-synuclein gene associated with Parkinson’s disease differentially affect cognitive sequence learning. Genes Brain Behav 2008;7:31–36.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50